HPLC_Greg said:The pharmacokinetics explain nearly every practical question asked here.
This is where I part company with the consensus forming above. The counter-case has not been addressed. Somebody upthread described the situation that does not fit, and the thread moved on rather than engaging with it, which is the failure mode this board is supposed to avoid.
One concrete data point for the thread. Numbers worth memorising for this class: Tmax one to three days for the weekly peptides, terminal half-life about a week for semaglutide and about five days for tirzepatide, steady state at four to five half-lives, subcutaneous bioavailability high enough that site choice is irrelevant.
RetaRick_CA said:Somebody upthread described the situation that does not fit, and the thread moved on rather than engaging with it, which is the failure mode this…
Adding the part of the answer the thread has not reached. If two explanations both fit, the useful question is which one predicts something the other does not. That is answerable; arguing about which sounds more plausible is not.
If somebody has the primary source to hand I would rather cite it than paraphrase it.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsA narrower follow-up, since the general answer is now clear:
Which effects tachyphylax and which persist, because the answer explains why tolerability improves while the appetite effect keeps working?
Closing the loop on my own question.
Closing this out: the trough rather than the peak explains the pattern I was seeing on day six, which I had been blaming on the vial.